November 8, 2016 / 11:42 AM / 9 months ago

BUZZ-Valeant Pharmaceuticals: Falls on Q3 results, FY forecast

** Canadian drugmaker's U.S. shares fall 9.6 pct to $17.30 premarket; most actively traded among NYSE-listed stocks

** Company reports 11 pct fall in Q3 revenue, cuts FY profit and revenue forecasts

** Valeant, which has debt of more than $30 bln, said last week it was in talks with third parties to sell its Salix stomach-drug business and other assets

** Up to Monday's close, stock had fallen 81.2 pct YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below